Acomplia

ACOMPLIA

Acomplia, also known as rimonabant, is a kind of anorectic drug used in the treatment of obesity. Its main function in the body is to selectively block the cannabinoid receptor, CB1, in the brain, the liver and gastrointestinal tract. It is said to be first of its kind that selectively block CB1, and the use of the drug is approved anywhere in the world. Its visible effect of the drug is a loss of appetite. The loss of appetite gradually leads to a loss of weight. Generally doctors suggest doing regular exercises and having a control on food consumption simultaneously with the intake of this drug for producing maximum effect. Usually this drug is prescribed for patients who have a body mass index of 30 kg/m2 or greater. This drug is most beneficial to people who has an abnormally large waistline. As of now, Acomplia is available in the markets of 56 countries in all under various trade names.

Acomplia affects the body by reducing the rate of glucose and fat metabolism through selectively blocking the CB1 receptors, thereby controlling the excessive activity of endocannabinoid system. Also the drug has an influence on the brain circuits that induce a feeling of hungriness in certain conditions, say when smoking cannabis. Mainly, this drug is used for the weight control in patients who are affected with Type 2 diabetes and excessive levels of fat in the blood. There is a school of thought that the drug can also be used to prevent or reduce the risk of heart diseases. Also, the drug has been proven to be fairly successful in forcing the people to quit smoking. A tendency to vomiting and nausea are the common side effects of Acomplia. It has been also observed that some patients tend to suffer from depression, after starting the drug usage.